Growth Metrics

AbCellera Biologics (ABCL) Intangibles (2020 - 2026)

AbCellera Biologics filings provide 7 years of Intangibles readings, the most recent being $37.5 million for Q1 2026.

  • Quarterly Intangibles fell 9.06% to $37.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.5 million through Mar 2026, down 9.06% year-over-year, with the annual reading at $38.4 million for FY2025, 8.86% down from the prior year.
  • Intangibles hit $37.5 million in Q1 2026 for AbCellera Biologics, down from $38.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $163.0 million in Q3 2022 and bottomed at $37.5 million in Q1 2026.
  • Average Intangibles over 5 years is $93.8 million, with a median of $118.7 million recorded in 2024.
  • The largest annual shift saw Intangibles skyrocketed 310.94% in 2022 before it plummeted 65.31% in 2025.
  • AbCellera Biologics' Intangibles stood at $131.5 million in 2022, then fell by 8.42% to $120.4 million in 2023, then plummeted by 65.03% to $42.1 million in 2024, then dropped by 8.86% to $38.4 million in 2025, then dropped by 2.4% to $37.5 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Intangibles are $37.5 million (Q1 2026), $38.4 million (Q4 2025), and $39.3 million (Q3 2025).